AU2003232019A1 - Measuring nitric oxide in blood gases and treatments based thereon - Google Patents
Measuring nitric oxide in blood gases and treatments based thereon Download PDFInfo
- Publication number
- AU2003232019A1 AU2003232019A1 AU2003232019A AU2003232019A AU2003232019A1 AU 2003232019 A1 AU2003232019 A1 AU 2003232019A1 AU 2003232019 A AU2003232019 A AU 2003232019A AU 2003232019 A AU2003232019 A AU 2003232019A AU 2003232019 A1 AU2003232019 A1 AU 2003232019A1
- Authority
- AU
- Australia
- Prior art keywords
- blood
- patient
- nitrite
- nitric oxide
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 title claims description 284
- 239000008280 blood Substances 0.000 title claims description 82
- 210000004369 blood Anatomy 0.000 title claims description 55
- 239000007789 gas Substances 0.000 title claims description 10
- 238000011282 treatment Methods 0.000 title description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 57
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 53
- 201000010099 disease Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 210000000601 blood cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- 206010021143 Hypoxia Diseases 0.000 claims description 18
- 230000004044 response Effects 0.000 claims description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 17
- 239000001301 oxygen Substances 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 229940124549 vasodilator Drugs 0.000 claims description 16
- 239000003071 vasodilator agent Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 210000002216 heart Anatomy 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 12
- 230000017531 blood circulation Effects 0.000 claims description 11
- 238000006213 oxygenation reaction Methods 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 description 20
- 102000001554 Hemoglobins Human genes 0.000 description 20
- 239000000243 solution Substances 0.000 description 19
- 238000005259 measurement Methods 0.000 description 15
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 4
- 230000005587 bubbling Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000000287 tissue oxygenation Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229940125691 blood product Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- 230000015843 photosynthesis, light reaction Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 235000010289 potassium nitrite Nutrition 0.000 description 2
- 239000004304 potassium nitrite Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- QVHMXAMSRLOKNC-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC=N2.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O QVHMXAMSRLOKNC-BTVCFUMJSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 238000010266 Sephadex chromatography Methods 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000006499 vasodilator function Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38359502P | 2002-05-29 | 2002-05-29 | |
| US60/383,595 | 2002-05-29 | ||
| PCT/US2003/013409 WO2003102575A1 (en) | 2002-05-29 | 2003-05-27 | Measuring nitric oxide in blood gases and treatments based thereon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003232019A1 true AU2003232019A1 (en) | 2003-12-19 |
Family
ID=29711927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003232019A Abandoned AU2003232019A1 (en) | 2002-05-29 | 2003-05-27 | Measuring nitric oxide in blood gases and treatments based thereon |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060088942A1 (https=) |
| EP (1) | EP1514103A4 (https=) |
| JP (1) | JP2005527834A (https=) |
| AU (1) | AU2003232019A1 (https=) |
| CA (1) | CA2487719A1 (https=) |
| WO (1) | WO2003102575A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010201151B2 (en) * | 2002-12-12 | 2012-12-13 | Duke University | Forming Iron Nitrosyl Hemoglobin |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2294543T3 (es) | 2003-07-09 | 2008-04-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal | Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares. |
| WO2009029836A2 (en) | 2007-08-31 | 2009-03-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes |
| RU2449783C2 (ru) * | 2010-08-02 | 2012-05-10 | Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" | Способ коррекции l-name индуцированного дефицита оксида азота l-норвалином в эксперименте |
| CN104159591A (zh) * | 2011-11-07 | 2014-11-19 | 通用医疗公司 | 红细胞的处理 |
| RU2500040C1 (ru) * | 2012-04-12 | 2013-11-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции l-name индуцированного дефицита оксида азота комбинацией тадалафила и l-норвалина в эксперименте |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992010228A1 (en) * | 1990-12-05 | 1992-06-25 | The General Hospital Corporation | Devices for treating pulmonary vasoconstriction and asthma |
| US5459076A (en) * | 1992-04-22 | 1995-10-17 | Brigham And Women's Hospital | Method for detecting nitric oxide, nitrosonium equivalents, S-nitrosothiols and S-nitroso-proteins in biological systems |
| US5427797A (en) * | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
| US6153186A (en) * | 1995-09-15 | 2000-11-28 | Duke University Medical Center | Red blood cells loaded with S-nitrosothiol and uses therefor |
| US6197745B1 (en) * | 1995-09-15 | 2001-03-06 | Duke University | Methods for producing nitrosated hemoglobins and therapeutic uses therefor |
| US6916471B2 (en) * | 1995-09-15 | 2005-07-12 | Duke University | Red blood cells loaded with S-nitrosothiol and uses therefor |
| US5869539A (en) * | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| US5885842A (en) * | 1996-11-08 | 1999-03-23 | Medinox, Inc. | Methods for the detection of nitric oxide in fluid media |
| EP1015490B1 (en) * | 1997-02-06 | 2004-04-14 | Duke University | No-modified hemoglobins and uses therefor |
| US6087087A (en) * | 1997-07-03 | 2000-07-11 | Takashi Yonetani | Treatment of hemoglobin with nitric oxide |
| US6314956B1 (en) * | 1999-09-08 | 2001-11-13 | Duke University | Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders |
| US6472390B1 (en) * | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
| WO2003066109A1 (en) * | 2002-02-08 | 2003-08-14 | Gambro, Inc. | Nitric oxide in a pathogen inactivation process |
-
2003
- 2003-05-27 AU AU2003232019A patent/AU2003232019A1/en not_active Abandoned
- 2003-05-27 JP JP2004509410A patent/JP2005527834A/ja active Pending
- 2003-05-27 WO PCT/US2003/013409 patent/WO2003102575A1/en not_active Ceased
- 2003-05-27 CA CA002487719A patent/CA2487719A1/en not_active Abandoned
- 2003-05-27 EP EP03756165A patent/EP1514103A4/en not_active Withdrawn
- 2003-05-27 US US10/516,250 patent/US20060088942A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010201151B2 (en) * | 2002-12-12 | 2012-12-13 | Duke University | Forming Iron Nitrosyl Hemoglobin |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060088942A1 (en) | 2006-04-27 |
| EP1514103A4 (en) | 2006-05-24 |
| JP2005527834A (ja) | 2005-09-15 |
| CA2487719A1 (en) | 2003-12-11 |
| EP1514103A1 (en) | 2005-03-16 |
| WO2003102575A1 (en) | 2003-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giunta et al. | Ozonized autohemotransfusion improves hemorheological parameters and oxygen delivery to tissues in patients with peripheral occlusive arterial disease | |
| McMahon et al. | Nitric oxide in the human respiratory cycle | |
| Aoki et al. | Effect of insulin on muscle glutamate uptake: Whole blood versus plasma glutamate analysis | |
| Nilsson et al. | Inverse relationship between age-dependent erythrocyte activity of methaemoglobin reductase and prilocaine-induced methaemoglobinaemia during infancy | |
| Hill et al. | A mathematical model of carbon dioxide transfer in the placenta and its interaction with oxygen | |
| US20070191478A1 (en) | Methods of treating cardio pulmonary diseases with NO group compounds | |
| Reeves | The effect of temperature on the oxygen equilibrium curve of human blood | |
| Dijkhuizen et al. | The oxygen binding capacity of human haemoglobin: Hüfner's factor redetermined | |
| Gutteridge et al. | Primary plasma antioxidants in adult respiratory distress syndrome patients: Changes in iron-oxidizing, iron-binding, and free radical-scavenging proteins | |
| Wilkes et al. | Respiratory, ventilatory, acid-base and ionoregulatory physiology of the white sucker Catostomus commersoni: the influence of hyperoxia | |
| Schwartz et al. | Late metabolic acidosis: a reassessment of the definition | |
| Portörő et al. | Towards a novel haemoglobin-based oxygen carrier: Euro-PEG-Hb, physico-chemical properties, vasoactivity and renal filtration | |
| US20060088942A1 (en) | Measuring nitric oxide in blood gases and treatments based thereon | |
| Westendorp et al. | Atrial natriuretic peptide improves pulmonary gas exchange in subjects exposed to hypoxia | |
| Boning et al. | Blood osmolality in vitro: dependence on PCO2, lactic acid concentration, and O2 saturation | |
| Inculet et al. | Altered leucine metabolism in noncachectic sarcoma patients | |
| Trevisan et al. | Hypertension, non-insulin-dependent diabetes, and intracellular sodium metabolism. | |
| Martinez et al. | Microvascular Consequences of Methemoglobin Compared to Reduced Hemoglobin in the Microcirculation | |
| Hlastala et al. | Hemoglobin-ligand interaction in fetal and maternal sheep blood | |
| Jahr et al. | Oxygen Saturation Measurements in Canine Blood Containing Hemoglobin Glutamer‐200 (Bovine): In Vitro Validation of the NOVA CO‐Oximeter | |
| Adamson et al. | Erythrocyte function and marrow regulation in hemoglobin Bethesda (β145 histidine) | |
| Winslow et al. | Normal whole blood Bohr effect in Peruvian natives of high altitude | |
| Danielsson et al. | Cardiovascular function and alveolar gas exchange during isovolemic hemodialysis with acetate in healthy man | |
| Pelikánová et al. | Decreased urinary kallikrein with hyperglycemia in patients with short-term insulin-dependent diabetes mellitus | |
| Robertson et al. | Red cell oxygen affinity in severe hypertriglyceridemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |